 | Up a level |
Bill, Ruben; Montani, Matteo; Blum, Benedikt; Dufour, Jean-François; Escher, Robert; Bühlmann, Michael (2018). Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver. Hepatology, 68(1), pp. 384-386. Wiley Interscience 10.1002/hep.29853
Koeberle, D; Dufour, Jean-François; Demeter, G; Li, Q; Ribi, K; Samaras, P; Saletti, P; Roth, A D; Horber, D; Bühlmann, Michael; Wagner, A D; Montemurro, M; Lakatos, G; Feilchenfeldt, J; Peck-Radosavljevic, M; Rauch, D; Tschanz, B; Bodoky, G; Swiss Group for Clinical Cancer, SAKK (2016). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Annals of oncology, 27(5), pp. 856-861. Oxford University Press 10.1093/annonc/mdw054
Merz, Tobias M; Schär, Pascale; Bühlmann, Michael; Takala, Jukka; Rothen, Hans U (2008). Resource use and outcome in critically ill patients with hematological malignancy: a retrospective cohort study. Critical care, 12(3), R75. London: BioMed Central 10.1186/cc6921
